MOR - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Julia Neugebauer

Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Senior Director Investor Relations at MorphoSys, and it is my pleasure to welcome you to our first quarter 2022 financial results conference call.

Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; Malte Peters, Chief Research and Development Officer; and Joe Horvat, U.S. General Manager.

Before we begin, I'd like to remind you on Slide 2 that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for commercialization of our products and our development plans, expectations for the compounds in our pipeline as well as the development plans of our collaboration partners. Form subject cause number differ December our those in are uncertainties risks materially XXst, statements report SEC described may annual documents time that actual the in XXXX, forward-looking and to year to of a and including for from These the and time ended other XX-F results MorphoSys. to of speak mind as to important statements our is that keep in today. of this It webcast on the agenda On for Slide X, will call. you find today's give we'll and outlook. overview an with begin will an Jean-Paul Joe the will and summary will Sung provide XXXX a commercial Mark development a quarter provide update, our on financial pipeline an results. of for call update our first before turning to

open Following Jean-Paul. over your call to for that, the these will questions. call prepared remarks, the I we With now hand

Jean-Paul Kress

Welcome, hematology for mission Thank the make everyone, today. In continued you in quarter, our progress on and leader us oncology. thank first a joining we to become you, to Julia.

commercial leader product, the first designated treatment, patient practice shortly. therapy now immunotherapy for line It preferred provide cancer second in new regimen a NCCN will commercial second for a is in Our guidelines. clinical updated DLBCL. update line the market Monjuvi, the remains Joe starts

robust strong pivotal a pipeline, have are in studies. Phase mature seeing We we patient and X and our enrollment

the and are diseases patient's on We potential hem-onc have are a myelofibrosis. to evaluating paradigm optimistic the these lymphoma believe have of difficult-to-treat non-Hodgkin's We change additional types positive about we lives. Monjuvi and in first-line pelabresib in to for impact treatment

remains in DLBCL, there large the a unmet opportunity largest Monjuvi need. see first-line we For where

in interest with we from to on enroll continues and well of our the confident to an three IPI approach, community, medical patients five. focusing frontline significant with high-risk are pivotal trial Our very

believe being be myelofibrosis excited very We than pivotal in a our combination could $X is billion standard of patients X studied first-line We with potentially and opportunity. of for which care with the potential trials in ruxolitinib. in pelabresib change about manifest opportunity myelofibrosis, pelabresib are the greater

EZHX In in autoimmune are basket our trial; we oncology the CPI-XXXX inhibitor late-stage programs, in mid-stage addition a to felzartamab pipeline, diseases. advancing our and

year. For expecting both programs, later are data we this

We focus opportunities front. is execute Monjuvi continue term our year and over on to long as major our sales development our value-creating The benefit patients of on our are commercially to stay to the the this and pivotal continue drive shareholders. priorities, enroll disciplined largest rapidly studies, which for the we potential and to both

announce about we the Roche this by potentially As programs. we excited to significant for in otilimab gantenerumab announce are in and AD; to is planning look pivotal data to two this year. arthritis partner data year, rheumatoid data of our readouts of for pivotal end GSK

we share and in imperfecta. Anthos lupus for study osteogenesis and treatment the prevention Ultragenyx Phase Therapeutics investigating a year. the pivotal advance for programs We to importantly, is that this a expected advance number Novartis are also studies expect Mereo pleased to Sjogren's to of X/X clinical into their thromboembolism. partners venous ianalumab advance setrusumab for are nephritis; Also, additional of to Most syndrome abelacimab and of

next provide attractive Malte trials. these late-stage to provide tend on streams with which information future will On royalties, programs, more we and pivotal commercial our programs. could potential on receive efforts income of we execute as this partner us wave

cash update. a a please? will to elaborative I that, As commercial half XXXX. position, data sheet, Joe runway pivotal very us first strong we have turn the in we look our our at Joe, our for through balance call takes financial now and over With

Joe Horvat

Thank you, Jean-Paul.

disease. full for XX% year-over-year sequential year of are immunotherapy, growth. On a Monjuvi a were uptake we this continued basis, pleased our the to with representing commercial results. net launch quarter the out XX%. with aggressive sales first decline we gradual Monjuvi million, of $XX.X novel in Turning of a the first Coming saw Monjuvi a in

look underlying only the omicron demand impacted it as X% wave. by the was If lower at by was demand, you

For further, greater from the care community XX% remainder of orders expect sites from the of balance than the results the down sequentially. academic the year, came from of grow sales setting. setting we to and the Breaking

of continue of orders reach end with were expand from repeat quarter, more care QX. launch of In sites Monjuvi. We the through XX% of to orders, ordering reflects than ongoing our which since of first the Monjuvi sites X,XXX care the use approximately

uniquely care, continue and As be repeat we we the to rates order profile. its consistently of high, due to would expect physicians Monjuvi more penetrate more to differentiated as attractive sites prescribe

the Monjuvi approved March, the for second-line new We further recognition in Monjuvi leading have continue potential for This share patients. second-line was a designated preferred as NCCN guidelines the label. In market these to by emphasizes patient of starts. regimen

outpatient which an duration these in update. over are in immunotherapies setting. the important forward, turn to emphasis part the is to time efforts the and benefit Education importance over of of is until more to effort R&D ongoing persistence. the to education of an move education we keeping we treatment As how focused An efforts are immunotherapy. on treatment this Malte believe on continue consistent increase will patients. as I'll patients evolve call improving We or be treatment prescribing patterns Monjuvi utilized that, duration importantly, other With on for the a for progression, lead to to

Malte Peters

Thank you, Joe.

that As are Jean-Paul have excited advance. mentioned, a we to strong we pipeline

across mid-stage pivotal and on We our rapid on and assets late- are X especially our studies. Phase focused enrollment

therapy. Based myelofibrosis. potential care latest be pelabresib the manifest X may myelofibrosis, on have the in myelofibrosis. of first-line adequately we ongoing Arm from patients care of But with JAK as our with change The exploring XX% only in pelabresib the trial treatment treatment this can of of treated pelabresib. with is X inhibitor. study myelofibrosis the is X standard for data first-line X with effectiveness to Phase trial, Phase believe myelofibrosis ruxolitinib, pelabresib the standard of a of for start and current safety ruxolitinib Let's combination of The manifest a in

new potential. manifest of be the from expect and the line an two We on report progressing summer, study trial at manifest from clinical is medical enrollment we presenting upcoming this data in conference half first The to translational pelabresib's well, top data of will and including data XXXX. trial this disease-modifying

have is tafasitamab and treatment with and Phase an cancer refractory For for relapsed a frontline tafasitamab, more first-line DLBCL, important and options. underway, patients indolent where is the The area a X studies lymphoma. there significant this living other in-mind, program, to study two we DLBCL immunotherapy new examining need treatment or for of frontline our - effective with expanding first-line patients living potential as

that current the score of patients with garnered community. significant high-risk enrolling trial and is plus IPI of to interest The trial we potential medical five, very have has pace in tafasitamab an confident our may focuses to are at design a care. the standard lenalidomide on enhance from and the three We believe promising

is initiated refractory Xencor, lenalidomide patient, combination are DLBCL. non-Hodgkin's and investigating has the we number that and a first first close partner, study this, trial, of schedule an The in plamotamab antibody, lymphoma. a MIND treatment study Our investigating our patients administration weight the visit reduced patient their to and the with relapsed with is for treating been CDXXxCDX have with tafasitamab Supplemental optimized of also first or in patients occurred. to

indications. We clinical this is antibody in readouts transatumab, the autoimmune and have development our in for EZHX anti-CDXX development oncology; mid-stage assets. second we from expect also two is for half assets: clinical data both year, our In inhibitor CPI-XXXX, of

Finally, year. we expect some and release of clinical programs data to this partners our programs -

successful history long may and be a companies. MorphoSys healthcare global with of has aware, you As partnerships strategic creating

collaborations. into an some While MorphoSys has company key transformed of meaningful integrated from to fee-for-service of research-based are some biopharma from excited programs our we company, being a arising progression see

advance from is to study data a also clinical And studies the Sjogren's for of of disorder an Factor against planning from with are imperfecta, disease. osteogenesis ianalumab, directed the of to shared bone First, investigating receptor antibody studies known is otilimab the in genetic nephritis. Roche we directed exploring pivotal BAFF its Phase study rheumatoid in Novartis a X expect Also, X/X the antibody planning GSK in a Mereo year, plans and Ultragenyx lupus syndrome this in the gantenerumab to X two graduate announce year, share into also arthritis. fourth for to year, thromboembolism. it advance venous an this recently Alzheimer's of treatment Anthos treatment quarter this pivotal and as abeluximab, as bone prevention Phase lastly, Therapeutics setrusumab disease. for against brittle data

flow steady the several years, data. to we of a expect over clinical So deliver next

of I'll excited about our call With pipeline. a the are over for Sung that, turn the now very progress our financials. potential of to We the review and

Sung Lee

quarter first our Thank results you, share the pleased Malte. financial We're to XXXX. of for

XX. Slide to Moving

first and quarter trial the the $XX.X As due by basis, XX%. growth demand. XX%, earlier, addition Monjuvi were XXXX, Joe declined fourth of in sales XXXX, clinical a that million On effects year-over-year the in the sequential to omicron stated to reflecting inventory quarter in dynamics of occurred sales of on largely purchases of

for. continue Monjuvi the U.S., which the of opportunity our excited outside is Incyte We be to for partner responsible

days launch compared was year-over-year a million in million milestone to sales Cost quarter Monjuvi Monjuvi. EUR quarter The revenues benefited XX.X of recorded X in in from Monjuvi of the the EUR of While EUR million were U.S. the period was XXXX, EUR sales year the million ago. X.X of EUR X.X cost the was sales GSK. million XX.X million, a to driven it's EUR quarter product million in first specific from to EUR the increase U.S. XXXX for XXXX. first ago. compared of sales in revenues early in first primarily Total by we higher Total in year X.X Prior there, year revenue royalty same XX payments of

quarter fees. reflects expenses for R&D was expenses support made XXXX. increased million the million of investments of XXXX. our additional to and in XX This compared legal XXXX. The decreased XX.X The expenses by launch. and same increase of of first XXXX Turning programs. to compared to Constellation the first higher XX.X XXXX XX.X quarter XX.X the the and to million operating to the first were of professional first constellation full quarter EUR inclusion in G&A million, the primarily in clinical-stage growth decline Monjuvi EUR EUR EUR the was year EUR million period investment first in expenses. EUR compared of the inclusion Selling primarily quarter quarter the year-over-year were in in XXXX of for of support of million, the driven the by to XX.X to XXXX, advancement the first driven

quarter loss XXXX. of of reported EUR we XX.X a XXX.X first net For compared EUR first million, of XXXX, net of quarter to the million the consolidated a loss in

XXX EUR sheet. half balance investments to and is of of quarter ended the amount million our of data the take the cash the first end to at EUR This to anticipated with in pivotal which Turning XXXX. sufficient We us million, readout, XXX first XXXX. through XXXX collaborative of is compared

have access $XXX a we in to As development million from reminder, funding of also million. to $XXX range Royalty the bonds Pharma

will will that amount the our is year. Nonetheless, the cash to We amount runway. drawn serve extend communicate later this exact drawn only

for to on Slide guidance Turning our XXXX XX.

are reiterating questions. aspects for call guidance. of we like With financial We would our that, the Operator? all open to

Operator

[Operator comes Instructions] James Please from go first ahead. Morgan Quigley, question Stanley. The

Your line now open. is

James Quigley

Great. for question. taking you Thank my

of the in overall there? could prescribing Monjuvi. R&D on term And also give new second started are came are could X to first idea of impact currently percentage what quarter trials? where sort where sort that see actually of a us guidance, NBRx in related noticed throughout spend idea of days, line but I how sense terms the still the then know get are year, range, to trying as you you is come have And and us possibility flow. you And and not expect get to was so you where of of managing below just how of much I a have to the share? the idea of - And there's behavior for any an Could I'm that related Firstly, give early cost to then starting - it's with if an to a and Phase given - Again, the then new in or you. impact you DLBCL, you Phase now to the your of on you sort where us any share early X of the you R&D a you indicators in how have of to in the where R&D are face showing of of the spend, brand won't cash change physicians? seen that, on can treatment positive you the of XXXX? duration evidence that you increase? in, in an leading you patient Thank change but trials. if any us the could give And

Jean-Paul Kress

your Thank you, R&D. your first part James. question, will the Joe and answer then of will take Sung

Joe Horvat

Yes. Thank you, James.

our small, profile but to in as one a We fluctuation Monjuvi to new of what are both differentiated opportunity as So two, see that. in continue is one are because with to the the do anticipate there's on improve that data see patient every it relapsed/refractory choice. patients we data we of There prescribed out relates starts, sets setting. every it preferred three is

in always months last last only to it arrears, six months duration as duration last have the year. and know, We six first of right? is treatment relates year of treatment, of As the you of

make this still and with multichannel as teams our increases early outpatient broad have immunotherapy goes support as a in choice, treatment message duration it's strong our leveraging deliver But differentiated continue engagements, we that the to an gradual days. in-person along. as continue So our we to year of as profile large to to feel look we'll approach of we're year, that uniquely success

Sung Lee

Okay. respect of of the that and with is James, to expenses this your R&D phasing for question remainder the the year. And Sung,

the Our guidance is board. across intact

expenses So move up year. we we through as do the expect R&D ramp to

expenses And XX%. about for look the there's on R&D So X, if Quarter no just been that increase increased change year-over-year you front. at

substantial. that's of a as So bolus through come as And that a pivotal studies. we're surprise pretty shouldn't moving

Now our are of for studies the to this XX% X studies. materials, expense, XX%, expenses mid-stage our we but gear that and our expenses, of over everything vast And closer R&D as R&D well, with CRO-related some R&D composition a regard the well also the majority, to clinical is of development. pivotal expenses running goes into have then Phase probably toward ongoing majority

Operator

the Jason next question Butler, JMP comes And from Securities.

Your line is open. now

Roy Buchanan

guess and the for It's positive couple Roy have a market follow-up factors, questions. reorder the Monjuvi Thanks high the Jason. for I share. you leading a on taking our commercialization So of on rate,

what's been questions so hesitant using receptivity the are, the decision? start main that I the two the So is the behind guess to question have driver Monjuvi, for the physicians that And what's other to educational guess And the share the efforts of utilization to patients you're being drive a to market half Thanks. getting to prescribed progression. are second-line third I to was then clarify the Monjuvi?

Joe Horvat

Yes.

So thanks, Jason.

that to profile, continue of we is early a Monjuvi and novel You're that immunotherapy of that patients using their focus data. more patients. response ensure new from the the key so it's treatment we think and awareness with volatility still leading differentiated hesitation as increase that it understanding a relates as some manage continue we market remain how patients this to And the on penetrate share. and third correct, half It's of overall, the what the to awareness. to of on are therapy long can to of patients the I reason to to small number the would numbers our and uniquely continue as understand raise lack stakeholders given a to see And But because say and any lack understanding I our can as And see in we appropriately days possible. so have of to expect launch. the in is month,

that So duration to a we expect build treatment. with see in this, gradual of

Roy Buchanan

sense. makes That Okay.

- so out it's is far me getting you've guess, seeing you seeing can there getting the of I how target physicians, you're there about of or where to touches physicians what percentage guess. I So marketed the out remind and more physicians. and the

Joe Horvat

not at opportunities increase, we out. No. We're get certainly XXX%. Obviously, to half. and there's always - to We're well continue over but

to and teams do and we getting Our improve, to are in-person high continue opportunities there's are But we to engagements, always seeing that. offices. access more

Roy Buchanan

there felzartamab Which see going is membranous impact year, we any from both updates Okay. and been Russia that then one nephropathy? And Great. to for be on in has trials? Ukraine for And might those first? this later IgA and the

Malte Peters

Yes.

planning So the for for both we trials the trials. provide for are updates to nephritis and IgA

AMN Of earlier. is you study it more the mature started as remember, more, course, because

for study, the Ukraine, the Russia, the going that data a study, compared nephritis toward going are the And provide With both trial. year. data is end nephritis we fully on IgA study be the is the of more to AMN set the remember enrolled. also study will enrolled, to to studies So excited information IgA and updates is to the bit and at, is fully currently for the to show share we respect where

the two on war referring studies that Russian-Ukraine the to. has So no was impact I

Operator

from question Berenberg. And the next Xian comes Deng,

Your line is now open.

Xian Deng

Thank for please. Two, Thank questions. my taking Hi. you you.

last is I effect one some inventory first there positives the mean, So were year, that, QX like on Monjuvi.

the as sales, full the the the remaining with third that you. QX year year? if the wondering, actually was are to the the think last wondering just sales are maybe you just I moving meet impact wondering the help was And line? the you full drivers second year Monjuvi making in of could DLBCL, quarter, line one elaborate So for into guidance? CAR-T your of also could this in And the Monjuvi second I guidance use within Thank your when thoughts is on Monjuvi is, I what bit were expectations a year, actually with the just in what more the for

Jean-Paul Kress

first Sung, your thank take will part, I you and second. Joe questions. the Great. Well, for

Sung Lee

Quarter that trials expectations happened in our the Thanks we inventory Yes, it that and in regard as such. of impact Quarter to With and for decline, those terms the communicated questions. of within to sequential clinical was X Xian. X, buy-in the range of

the look we're to quarter over the QX. that million decline you to of buy-in and And inventory $X as is to result swing a quarter, absolute in demand lower of balance if due $X.X the at So due is down of dollars, purely related million omicron. million the overall $X.X the then

range So within it expectations. of our was

then to terms of these of very you there Continuing the and of penetrating and there, drive in in to to mind. persistence additional Now down get bit the various sites drivers comes that range a to the guidance, have variables: is so quite to three is of It endpoints uptake; care. important, patient keep

So continue safe half early on. that larger to to it's second than do half. focus these proportionately But expect are to year, assume the the similar first And things it's days. team commercialization last to we the be

Joe Horvat

And as we it population plus on market. line second always relates to the is competitive anticipated And the your a question CAR-Ts. that

However, proposition almost we the of and of with feel strong good The value important, XX% are brings. academics the about to Monjuvi support continue academics representing our see that care. we sites

profile we for the Monjuvi as have As past, those in a immunotherapy the mentioned the patients differentiated relapse refractory study. outpatient uniquely in does choice

in So patients we continue feel to that second-line will setting. the benefit

Operator

And Citi. the Agarwal, from Vineet next question comes

now line is open. Your

Vineet Agarwal

my Hi. taking question. Thanks for

first, the top I recent And running you tafacitumab in helpful plans Incyte trial, your clinical understand is confirm for handicaps to is trial, if any trying quarter? combination is if any there trial there PIXK just contribution purchases would in mean - Incyte is Basically, your I from in quarter, no this So this million it PIXK, the should get on AdCom thoughts. revenues we can CLL your the with given to but $XX the this assume indication. being understand be FDA longer pursued?

Jean-Paul Kress

you, question. Vineet Okay. your Well, thank for

for delta. we'll financial to Let's Sung the question PIXK in start Malte and by the go

Sung Lee

thanks X. answer The Quarter trial is Yes. there no simple were no, clinical in the Vineet, sales for question.

Malte Peters

Yes.

referred So to the FDA. the conducted impact recently committee advisory of at you for that

some any for a ongoing happy all, FDA's that parsaclisib the kinase to that say combination, mind are of do the from inhibitor. see not PIXK true we I have opinion. we frontline, First impact It studies, coming impact do there in that because they and on may think not be is the

is kinase - I of doublet is think in the combination very active. the in delta PSC with tafasitamab BDA because we remaining there active combination in actually very is are interest this that's CLL. combination because The

programs us But Incyte and data by kinase conducted opinion I to are it's these the going that be in that studies that impact, are gone Incyte. the clear situation, interested will has clear did by these both I think generate. And PIX So guided FDA's for think And have and the remain it's up. delta the bar some combinations. development we

Vineet Agarwal

XX% spread in If I squeeze to great. any that on How that, your color head If that add you would be the more in count first quarter. the can about one function? across reduction is could of

Sung Lee

This is give to again, Yes. Happy you some on Sung Vineet. color that.

Germany where announcement start the all recall our we the now. the of So at consolidated have organization a consolidation where did of year in that made we research that's Planegg,

say was would saw certainly you decline. reasons I major the quarter-on-quarter one headcount So that why of

it. I a think to it's fair that's significant the or So think of majority

Operator

from question the And Stifel. Victor next Floc'h, comes

Your line is now open.

Victor Floc'h

Yeah. and Thanks for one question. about two I taking felzartamab. on actually, have one Monjuvi my

should is as part it the momentum to corporate quarter? First second next least you've wait we been pretty as not was inflection Monjuvi's one, always a felzartamab, And year? on that Or for of you. the likely it well, an clear for in see at soon

an Thanks. was significant out-licensing I year we this so deal potentially data enough expect to to it? drive wondering, should be for expected And

Jean-Paul Kress

Victor. can the take I'll you, the and thank take Well, Joe Monjuvi question first question.

exciting indicated hematology meaning had is that We it as authorities, right. not our oncology. of in You're area really as

it's So to but that We ongoing. signaled more data the related comment or do and are And we waiting It's data, some have it's opportunities. really that. partnership said actually potential we are further. licensing we for contemplating can't that to not

ongoing, are what with happen we have data could it some but in with enriched these we later, It earlier. as mentioned could hand. So initiatives be

on tuned this one. Joe? stay So

Joe Horvat

Perfect. Victor. Thanks,

quarter utility and a these that before, we With Monjuvi. that driving mentioned focus we over all growth on broadening patients combined, to and through treatment. continue of penetrating differentiated And move the quarter. leading accounts the and gradual to as sequential we forward, new Sung see duration As increasing more message of

go year. see expect we the So we that's would as what through to

Operator

ahead. And Instructions] go comes Ebrahim, question Please next from JPMorgan. the Zain [Operator

line open. Your now is

Zain Ebrahim

Thank you my for question. taking

beyond My Just two, if is I question may. first QX.

sequential But expected also seeing sales of therapy? expectations any sequential disruption gradual there? us from second outbreak in variant growth your on $XXX ambition you're seeing million just you. Thank of talked growth You U.S. on what and what or of peak average you're And the remind BA.X Monjuvi. my Can store about the for same duration Monjuvi. question, your you for

Jean-Paul Kress

had question. We a to of of first halftime a the hear bit part the

Sung Lee

The you I Monjuvi to It's if of I ask second that moving any with think, - relative bottom first the do then there while had a waves toward part safe we're been albeit guidance, has also that to start are it's $XXX our million COVID we've the the a half would range question we've headwinds correctly, we probably different of I gradual further of two achieve expect the end you the to increases, two consecutive remains the COVID and pushed reiterating going the regard comment of Zane, trending think $XXX the row growth in outsized back to peak Obviously, out be product Joe years. half. the our Monjuvi. guidance. expect sales heard variants. the million with had, years, that made, peak first heard range, we COVID to sales, the to we had to goal Look, a with I question same. sequential outbreaks including that And this with guidance. is impact in that our But be of the goal years peak to a to potential situation. the And on couple and in is assume

Operator

Deutsche from And comes Rajan Sharma, next question Bank. the

line is Your open. now

Rajan Sharma

question. Thanks the Hi. for

and more duration couple a Just just more Monjuvi little push can maybe on I bit a of commercialization therapy. the on of

therapy then March, I year you. update And results provide Could duration was of Monjuvi on Thank update three months? think mentioned around you full now? could currently on secondly, therapy an of us just you on number patients at update the you that right in that?

Joe Horvat

Thank Rajan. for Yes, question. that you

we the earlier, As arrears. is of - I mentioned always duration treatment as in

data months we're from the of the last last So collecting we year. do and year, have six of year, months data first this six last from

it's And treatment say still But work fully the we -- months. on. that to few it expect second suffice question managing continue as we extending by and increase that to that - the related the in that duration So year of of at range will expectations, and goes a

Jean-Paul Kress

patients on of Monjuvi. Number

Joe Horvat

of last on patients call launch. at patients we Monjuvi. Monjuvi over believe since Number we've that been got prescribed the reported now I that have X,XXX

patient continue our we So to and reflected share. that's get in and market leading strong penetrate new starts,

Jean-Paul Kress

I patients have couple exceeded months, that we who would an greatly also add, Yes. this Rajan, have of is which average.

We some of patients a who have treatment. more year than have

who we months the have think since patients I a couple launch. of XX have

together - by our has seen market, And dominated market, a educating in is of Joe and here It's earlier, a great study. L-MIND of treat to - news regimen. said have it's comes produce our obviously, longer, immunotherapy question it's that the we we change in So the strength articulated that possible possible question, been with life as opportunity to bigger what the in leverage our in the we actually as which a can it's the in - chemo. the on real it

So it's the a But it. have that. the focusing data process. we obviously, we teams totally for And on have

Rajan Sharma

follow-up, And Okay. you. maybe if Thank I can. just one

this from that range drug realistic? say quarter the it kind of that for is has to XXXX guidance Monjuvi, gone year Given first the your way of fair is the

Joe Horvat

terms uptake the I'm said, the extending a And in ahead the obviously, of But the therapy. of of increasing pieces number not dissect of to have we're Monjuvi the care guidance, Well, of we of and Rajan, as us. reiterated of just going task big I guidance. sites penetration we duration and focused on,

the a there's those the variables bottom range. So any to and top be the end get you swing of in could of that wide

Operator

it further haven't hand I we received point. back to will you, Julia. questions And this at

Julia Neugebauer

call. and this remainder of conference available joining again, of the up, concludes and follow day. relations you today's good goodbye. gentlemen, a our the any Ladies day to Once Have is investor the thank call. team for like If you would for

MorphoSys (MPSYF) 9 May 222022 Q1 Earnings call transcript